Compare prices and buy ACE-031 from 3 research peptide vendors - also called suppliers or sources. Updated daily.
Sold under the name ACE-031, the research peptide indexed here is a 24-residue synthetic peptide (CAS 1621169-52-5) that its vendor listing and FDA's substance registry identify as a myostatin inhibitory peptide, a fragment derived from the mouse myostatin prodomain. It is a different molecule from Acceleron Pharma's ACE-031 (ramatercept), a recombinant activin receptor type IIB fusion protein. In laboratory and mouse studies, peptides from this series bound myostatin and are thought to block its signaling, which limits skeletal muscle growth. It has no FDA approval and no registered human trial.
For research purposes only. Not medical advice.
The research peptide sold as ACE-031 is a single synthetic chain of 24 amino acids, AWRQNTRYSRIEAIKIQILSKLRL with an amidated C-terminus, taken from the mouse myostatin prodomain. FDA's substance registry holds that sequence under the name Myostatin inhibitory peptide 7 (UNII U8DGS69FVC) and records CAS 1621169-52-5 against it. PubChem's record for the same molecule gives the formula C133H227N43O33 and a molecular weight of about 2957.
Acceleron Pharma's ACE-031 is a different substance with its own registry entry: ramatercept, UNII 42HQC6QLEK and CAS 1169766-01-1, a dimer of two 343-residue chains that fuse the extracellular domain of the activin type IIB receptor to an immunoglobulin G1 Fc region, with a calculated mass near 77,500 daltons. The two molecules share a development code and a target. One is a short synthetic peptide, the other a recombinant protein some twenty-six times its mass.
The category's other myostatin-axis entry is Follistatin 344, and the pathway itself is covered on the Growth Hormone and Muscle page.
The evidence for the sold sequence is preclinical. A medicinal-chemistry group at Tokyo University of Pharmacy and Life Sciences derived minimum inhibitory peptides from the mouse myostatin prodomain and reported that its 24-residue and 23-residue peptides bound human myostatin with dissociation constants of 30 to 36 nanomolar, and that the 24-residue peptide increased muscle mass in a mouse model of Duchenne muscular dystrophy (Takayama, Journal of Medicinal Chemistry, 2015).
Later work from the same group modified the sequence. Replacing its N-terminal tryptophan with a naphthyloxyacetyl group produced a derivative about three times more potent in a cell reporter assay (Takayama, ChemMedChem, 2016), and a chain-shortened 16-residue analog increased both muscle mass and hind limb grip strength in dystrophic mice (Takayama, ACS Medicinal Chemistry Letters, 2019). The group's own review describes the proposed binding mode as a computer simulation placing the peptide at the activin type I receptor binding site of myostatin, and notes that inhibition of myostatin by small molecules and peptides is less advanced than inhibition by antibodies and receptor decoys (Takayama, Chemical and Pharmaceutical Bulletin, 2022).
PeptideScouter found no human study of the sequence. As of October 21, 2026, ClinicalTrials.gov holds no record of it by registry name or sequence, and PubMed and Europe PMC return nothing by sequence.
Two published trials gave people the fusion protein.
Neither trial administered the peptide. Both gave ramatercept, so every human safety and muscle-mass finding published under the name ACE-031 describes the fusion protein and not the material in a research vial.
Ramatercept's development ended without an approval. FDA's Drugs@FDA database returns no matches for ramatercept or ACE-031, and ClinicalTrials.gov marks both Duchenne studies terminated, the ascending-dose trial and its open-label extension, each giving preliminary safety data as the reason.
For the peptide, PeptideScouter found no US regulatory record. As of October 21, 2026, the peptide appears in none of the following, and ramatercept appears only in the last:
No. They are two different substances with separate FDA registry entries. The research peptide sold under the name is a 24-residue synthetic peptide from the mouse myostatin prodomain, filed as Myostatin inhibitory peptide 7 with UNII U8DGS69FVC and CAS 1621169-52-5, with a molecular weight of about 2957. Acceleron Pharma's ACE-031 is ramatercept, UNII 42HQC6QLEK and CAS 1169766-01-1, a recombinant dimer of two 343-residue chains joining the extracellular domain of the activin type IIB receptor to an immunoglobulin G1 Fc region, with a calculated mass near 77,500 daltons. They share a development code and a molecular target, not a structure.
Not in any study PeptideScouter could find. As of October 21, 2026, ClinicalTrials.gov holds no record of the 24-residue peptide, searched by its registry name and by its sequence, and searches of PubMed and Europe PMC by sequence return nothing. The published work on the sequence is preclinical: binding assays and mouse studies reported by a group at Tokyo University of Pharmacy and Life Sciences from 2015 onward. The human trials run under the name ACE-031 administered ramatercept, a recombinant fusion protein, not this peptide.
The trials that were stopped tested ramatercept, the activin receptor type IIB fusion protein, not the research peptide sold under the same code. A randomized, double-blind, placebo-controlled ascending-dose Phase 2 trial in ambulatory boys with Duchenne muscular dystrophy, sponsored by Acceleron Pharma, was stopped early over potential safety concerns the authors identify as epistaxis, meaning nosebleeds, and telangiectasias, small dilated blood vessels (Campbell, Muscle Nerve, 2017). On ClinicalTrials.gov that study and its open-label extension are both marked terminated, each citing preliminary safety data.
Myostatin restrains skeletal muscle growth, and the peptide sold as ACE-031 comes from the prodomain that holds myostatin inactive in its precursor form. In the study that identified it, the 24-residue peptide and a 23-residue counterpart bound human myostatin with dissociation constants of 30 to 36 nanomolar, and the 24-residue peptide increased muscle mass in a mouse model of Duchenne muscular dystrophy (Takayama, Journal of Medicinal Chemistry, 2015). A later review by the same group describes the proposed binding mode as a computer simulation placing the peptide at the activin type I receptor binding site of myostatin. All of that work is preclinical.
No, and neither is ramatercept, the fusion protein that carried the ACE-031 code through clinical development. As of October 21, 2026, FDA's Drugs@FDA database of approved and tentatively approved applications returns no match for either, and neither appears in FDA's Category 2 list of bulk substances raising significant safety risks or in its lists of substances nominated for compounding under Sections 503A and 503B. Ramatercept's two Duchenne muscular dystrophy studies are marked terminated on ClinicalTrials.gov, each citing preliminary safety data.
ACE-031 is sold by 3 research peptide vendors indexed on PeptideScouter, with 4 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
All 3 indexed research peptide vendors currently have ACE-031 in stock. Stock state is refreshed daily from each vendor's catalog.
Disguised Alpha currently lists ACE-031 at $59.99/mg, the lowest listed price across 3 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $53.99/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 3 vendors listing ACE-031 publish a PeptideScouter code, worth 10% off. Applied, the lowest effective price falls from $59.99/mg listed to $53.99/mg at Disguised Alpha. Each vendor's code is shown beside its price in the table above.
ACE-031 ranges from $59.99/mg to $138.95/mg across 4 listings from 3 research peptide vendors, normalized to USD per milligram and refreshed daily.
3 research peptide vendors currently list ACE-031 on PeptideScouter. We track 4 listings across size and kit variants.
ACE-031's CAS Registry Number is 1621169-52-5.
